NCT05531097View on ClinicalTrials.gov

Ascending Single-Dose and Multiple-Dose Study to Evaluate HSK31679 in Healthy Subjects and Subjects With Elevated LDL-C

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

September 21, 2022

Study Completion Date

December 8, 2022

Conditions
HealthyElevated LDL-C
Interventions
DRUG

HSK31679

Single or multiple oral doses of HSK31679

DRUG

Placebo

Matching placebo

Trial Locations (2)

Unknown

Peking University First Hospital, Beijing

Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY